OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Van Tine on Sequencing Therapies in GIST

March 27th 2015

Brian Van Tine, MD, PhD, assistant professor of medicine, Division of Oncology, Section of Medical Oncology, Washington University School of Medicine, discusses sequencing in gastrointestinal stromal tumors (GIST).

Dr. Alan Miller on Immunotherapy for Cancer Treatment

March 26th 2015

Alan M. Miller, MD, PhD, Director of the Baylor Charles A. Sammons Cancer Center and Chief of Oncology for the Baylor Health Care System, discusses immunotherapy for cancer treatment.

Dr. Dawson on Increasing Causes and Unmet Needs in HCC

March 26th 2015

Laura Dawson, MD, Princess Margaret Hospital, University of Toronto, discusses increasing cause of hepatocellular carcinoma (HCC) and unmet needs related to the disease.

Patricia Hofstra on Alternatives to Acquisition in Healthcare

March 25th 2015

Patricia Hofstra, attorney, Duane Morris, discusses options that independent oncology groups have other than being acquired by larger healthcare or oncology systems.

Dr. Lynch on Expanding Molecular Subsets in NSCLC

March 25th 2015

Thomas J. Lynch, MD, director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital at Yale-New Haven, Giant of Lung Cancer Care, discusses expanding the number of molecular subsets in non-small cell lung cancer (NSCLC).

Sam Donaldson on the Need for Optimistic Doctors

March 24th 2015

Former ABC News reporter Sam Donaldson, a melanoma survivor, describes the need for optimistic but realistic doctors.

Dr. Sledge on Using PCR To Determine Therapy Benefit for Breast Cancer

March 24th 2015

George W. Sledge, Jr., MD, professor of medicine, Stanford University School of Medicine discusses the benefits of using pathological complete response rate (PCR) to understand therapy benefit in breast cancer.

Dr. Bijal Shah on Bortezomib's Impact on Treatment of MCL

March 24th 2015

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses the impact of the approval of frontline bortezomib for the treatment of mantle cell lymphoma (MCL).

Dr. Lacouture On Preventing Dermatological Adverse Events in Melanoma

March 23rd 2015

Mario E. Lacouture, MD, a dermatologist with Memorial Sloan Kettering Cancer Center, explains how providers can manage adverse events that result from melanoma therapies.

Dr. Weber on Molecular Testing in Melanoma

March 23rd 2015

Jeffrey Weber, MD, PhD, a senior member at the Moffitt Cancer Center, discusses the significance of molecular testing for patients with melanoma and when testing should occur.

Dr. Wierda on RESONATE-2 Trial Predictions for Patients With CLL

March 20th 2015

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center in Houston, discusses upcoming RESONATE-2 trial results for patients with chronic lymphocytic leukemia (CLL).

Dr. Battiste on Biomarkers in Glioblastoma

March 19th 2015

James Battiste, MD, PhD, assistant professor at the University of Oklahoma department of neurology and researcher at Stephenson Cancer Center, discusses research in glioblastoma (GBM).

Dr. Koo on Active Surveillance Rates in Prostate Cancer

March 19th 2015

Alec Koo, MD, FACS, managing partner, Skyline Urology, board of directors, LUGPA, discusses results from a recent study on active surveillance in prostate cancer.

Dr. Phan Discusses Challenges With Treating pNETs

March 19th 2015

Alexandria Phan, MD, the director of GI Medical Oncology at Houston Methodist, discusses some of the challenges oncologists face with treating patients with pancreatic neuroendocrine tumors (pNETs).

Dr. Luke on PD-1 Agents as Frontline Immunotherapy in Melanoma

March 13th 2015

Jason J. Luke, MD, FACP, assistant professor of medicine, Melanoma and Developmental Therapeutics Clinic, University of Chicago Medicine, discusses PD-1 inhibitors nivolumab and pembrolizumab as frontline immunotherapy choices for patients with melanoma.

Dr. Memarzadeh on Hormonal Therapy for Endometrial Tumors

March 13th 2015

Sanaz Memarzadeh, MD, associate professor of obstetrics and gynecology and the director of the Gynecologic Oncology (GO) discovery Lab at UCLA, discusses the benefits of hormonal therapy for endometrial tumors.

Dr. Voss on Early Efficacy Signals in DART Study for Advanced Kidney Cancer

March 12th 2015

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses early efficacy signals in the phase I/II DART study.

Dr. Pegram on Neoadjuvant Treatments for HER2-Postive Breast Cancer

March 11th 2015

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, discusses optimizing neoadjuvant treatments for HER2-positive breast cancer.

Dr. Jagannath on Immunotherapy in Multiple Myeloma

March 10th 2015

Sundar Jagannath, MD, director of the multiple myeloma program, professor of medicine (hematology and medical oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses immunotherapy in multiple myeloma and how it fits into the future treatment paradigm.

Dr. Charles Ryan on Abiraterone in mCRPC

March 9th 2015

Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the effects he has seen abiraterone have in patients with metastatic castration-resistant prostate cancer (mCRPC).